Alteogen Secures Safety in Domestic Phase 1 Clinical Trial of Biosimilar ALT-9
[Asia Economy Reporter Minji Lee] Alteogen announced on the 4th that it secured safety and confirmed efficacy in the domestic Phase 1 clinical trial of the Eylea biosimilar ALT-9. Eylea is an anti-VEGF agent widely used as a treatment for various retinal diseases such as macular degeneration, diabetic macular edema, and diabetic retinopathy.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
The company stated, "We plan to conduct subsequent global Phase 3 clinical trials in a total of 13 countries including Korea, Japan, and Europe," adding, "Entry into Phase 3 is scheduled for the fourth quarter of this year or the first quarter of next year, with product approval targeted for 2025."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
